Pfizer Net Income/Loss 2010-2025 | PFE
Pfizer annual/quarterly net income/loss history and growth rate from 2010 to 2025. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Pfizer net income/loss for the quarter ending March 31, 2025 was $2.973B, a 4.8% decline year-over-year.
- Pfizer net income/loss for the twelve months ending March 31, 2025 was $21.850B, a 16.89% increase year-over-year.
- Pfizer annual net income/loss for 2024 was $8.062B, a 273.59% increase from 2023.
- Pfizer annual net income/loss for 2023 was $2.158B, a 93.13% decline from 2022.
- Pfizer annual net income/loss for 2022 was $31.407B, a 42.6% increase from 2021.
Pfizer Annual Net Income/Loss
(Millions of US $) |
| 2024 |
$8,062 |
| 2023 |
$2,158 |
| 2022 |
$31,407 |
| 2021 |
$22,025 |
| 2020 |
$9,195 |
| 2019 |
$16,056 |
| 2018 |
$11,188 |
| 2017 |
$21,355 |
| 2016 |
$7,246 |
| 2015 |
$6,986 |
| 2014 |
$9,168 |
| 2013 |
$22,072 |
| 2012 |
$14,598 |
| 2011 |
$10,049 |
| 2010 |
$8,288 |
| 2009 |
$8,643 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$129.797B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
